VIROLOGY PROGRAM Approximately 20% of all cancers result from infectious agents, with the majority of these malignancies being virus-associated cancers. The Virology Program (VIR) focuses on deciphering the basic mechanisms by which human tumor viruses are linked to the development of malignancy. The long-term goal of VIR is to understand viral perturbation sufficiently to generate new therapies, including small molecules, biologics, and vaccines that target viruses and viral cancers.
The aims for VIR are focused on five research areas. These include understanding: (i) Viruses and Immunity (ii) Virus-Cell Interactions (iii) Viral Pathogenesis and Tumorigenesis (iv) Cancers impacted by HIV infection, and (v) Clinical & Translational Virology, which includes gene therapy, immune therapy and global oncology. Recent discoveries include the finding that virus-infected cells secrete exosomes or extracellular vesicles, which modulate the tumor environment, and the discovery that viral- encoded microRNAs contribute to the development of neoplasms. Additional findings focus on the modulation of innate immune signaling pathways by oncogenic viruses, epigenetic modifications in the context of viral cancers, and development of new therapies for AIDS-associated cancers. VIR also provides the scientific underpinnings of the UNC Lineberger Global Oncology effort, which is tightly integrated with other NCI- designated cancer centers, NCI-funded collaborative groups including the AIDS Malignancy Consortium in the US and Africa, and the NIH global research agenda. There are 23 program members from 10 different departments across campus. These faculty investigators have 39 research grants and $9.7 million (direct costs) in annual extramural support including $2.4 million from NCI and $5.5 million from other peer and other NIH. Members authored a total of 407 cancer-relevant publications during the past 5 years; 13% were intra- programmatic, and 16% were inter-programmatic. VIR is the administrative home of LCCC viral vector/gene therapy efforts and based on overlapping biology is working closely with the Immunology (IMM) research program. LCCC?s humanized mouse program is led by Victor Garcia?s work in VIR. There are extremely accomplished investigators in VIR including Dr. Jack Griffith, elected to the National Academy of Sciences, Dr. Raab-Traub, National Cancer Advisory Board member, and Dr. Damania who serves on the NCI Board of Scientific Counselors. Research in VIR is informed by the Office of Community Outreach and Engagement particularly with respect to HPV-associated cancers with an emphasis on translational studies related to human papilloma virus (HPV) including recruitment of new faculty and investment of pilot funding. HPV-associated cervical and oral cancers are of particular interest to LCCC as the incidence of HPV-associated cervical and oral cancer in our catchment area exceeds the national average.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089814
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Anderson, Chelsea; Engel, Stephanie M; Anders, Carey K et al. (2018) Live birth outcomes after adolescent and young adult breast cancer. Int J Cancer 142:1994-2002
Gralinski, Lisa E; Sheahan, Timothy P; Morrison, Thomas E et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. MBio 9:
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563

Showing the most recent 10 out of 1525 publications